Whooping cough, or pertussis, is making an unwelcome comeback in Norway. After years of low incidence, cases have surged since 2023, with the sharpest rise among infants under one year old. The Norwegian Institute of Public Health reported hundreds of cases annually, a stark contrast to the near-elimination seen a decade ago. The resurgence is not a mystery: too many infants are receiving their first vaccine dose after the critical window of vulnerability has already opened. This is a story about timing, biology, and the quiet ways public health systems fail when schedules slip.

The Window That Keeps Closing

Pertussis is a bacterial infection caused by Bordetella pertussis. It is highly contagious, spreading through respiratory droplets when an infected person coughs or sneezes. For infants, the disease is brutal. They can develop severe coughing fits that lead to apnea, turning blue, and in some cases, pneumonia or brain damage. Death is rare in high-income settings, but when it happens, it is almost always in an unvaccinated or partially vaccinated baby.

The Norwegian immunization schedule recommends the first dose of the diphtheria-tetanus-pertussis (DTaP) vaccine at six weeks of age. But that is already late. Maternal antibodies, passed across the placenta, wane within weeks. By the time a baby is two months old, those antibodies offer little protection. The window between the loss of maternal immunity and the development of the infant's own immune response after vaccination is a dangerous gap.

That gap is exactly where the resurgence is happening. Norwegian data from the Norwegian Institute of Public Health show that the highest hospitalization rates are in infants under six months, many of whom have had only one dose or none. The vaccine is not immediately protective; it takes two doses, typically given at six weeks and three months, to build meaningful immunity. In the meantime, a baby exposed to pertussis is vulnerable.

Why is the window closing? Delays in vaccination are common. Parents may postpone due to minor illness, logistical hurdles, or simply because they do not realize how serious the disease can be. Missed appointments are rarely rescheduled promptly, and catch-up vaccination is often forgotten. The system relies on parents to be proactive, but the consequences fall hardest on those who cannot navigate it.

Why the Schedule Matters Biologically

The biology of pertussis explains why timing is everything. Maternal antibodies, transferred during pregnancy, offer passive protection for the first few weeks of life. But these antibodies are short-lived, and their levels drop rapidly. By six weeks, most infants have very little circulating antibody. The vaccine, on the other hand, takes time to work. The acellular pertussis vaccine, used in Norway and most high-income countries, requires multiple doses to stimulate a robust immune response.

The first dose at six weeks primes the immune system, but it does not confer full protection. The second dose, given at three months, boosts the response. Even then, immunity is not complete until the third dose at five months. This schedule leaves a vulnerable period between the waning of maternal antibodies and the completion of the primary series. Bordetella pertussis exploits this gap, infecting infants who are too young to be fully vaccinated.

Researchers have explored ways to close this window. One approach is maternal vaccination during pregnancy, which boosts the antibodies transferred to the baby. This strategy has been adopted in several countries, including the UK and the US, and has shown significant efficacy in protecting newborns. Another approach is cocooning, where close contacts of the infant are vaccinated to reduce the risk of transmission. Both methods have limitations, but they address the same biological reality: babies need protection before their own immune system can respond.

The acellular vaccine itself is a factor. It was introduced in the 1990s to replace the whole-cell vaccine, which had higher rates of side effects like fever and local reactions. But the acellular vaccine may provide shorter-lived immunity, requiring booster doses in adolescents and adults. This is not a flaw in the Norwegian schedule alone; it is a global challenge. The key is to ensure that infants receive their doses on time, because the biology does not wait.

The Numbers Behind the Resurgence

The statistics from Norway are sobering. In 2023, the Norwegian Institute of Public Health recorded over 1,200 cases of pertussis, a fivefold increase from the previous year. The trend continued into 2024, with the highest incidence among children under one year. Hospitalization rates for infants are disproportionately high, with some estimates suggesting that one in three infants with pertussis requires hospital care. Deaths are rare, but they occur, and each one is a tragedy that could have been prevented.

These numbers are not unique to Norway. Across Europe, pertussis cases have been rising since the COVID-19 pandemic disrupted routine immunization. The pandemic led to missed well-child visits, and many children fell behind on their vaccines. In Norway, the national coverage rate for the DTaP vaccine remains high, above 95% for the full series, but the timeliness of the first dose is the weak point. Even a small delay in the first dose can translate into a large number of vulnerable infants.

The data also reveal a geographic pattern. Cases are clustered in areas with lower vaccination coverage, often in urban centers where vaccine hesitancy is more prevalent. This is not a simple story of anti-vaccine sentiment; it is also a story of access. Parents who work multiple jobs may struggle to take time off for appointments. Clinics may have limited hours. The system assumes that parents will prioritize vaccination, but it does not always make it easy.

What is most concerning is the potential for the resurgence to accelerate. Pertussis is cyclical, with peaks every three to five years. The current surge may be the beginning of a larger epidemic. Without intervention, more infants will be hospitalized, and the burden on the healthcare system will grow. The numbers are a warning, not a verdict.

What Slips the Schedule

Why do infants miss the window? The reasons are varied and often intertwined. Vaccine hesitancy, fueled by misinformation, is one factor. Some parents worry about vaccine safety, despite decades of evidence showing that the DTaP vaccine is safe and effective. Others are swayed by online claims that whooping cough is a mild disease, which is dangerously wrong for infants.

Healthcare access is another barrier. In Norway, the public health system provides free vaccinations, but parents still need to make appointments. Missed appointments are common, and clinics may not have the capacity to follow up aggressively. Catch-up vaccination is often an afterthought, and a missed dose can slip through the cracks. Digital reminders, such as text messages or app notifications, have shown promise in reducing no-shows, but they are not universal.

The COVID-19 pandemic exacerbated these issues. During lockdowns, many parents skipped routine visits out of fear of infection. When services resumed, the backlog was immense. Some children are now behind by months, and catching up requires a concerted effort that has not always materialized.

There is also a cultural dimension. In Norway, trust in public institutions is generally high, but vaccine hesitancy is not absent. A small but vocal minority spreads doubts, and social media amplifies their messages. Public health authorities have responded with information campaigns, but these take time to change minds. In the meantime, the window remains open.

Antibiotic Resistance Complicates Care

When pertussis is diagnosed, treatment typically involves macrolide antibiotics such as azithromycin. These drugs are effective in reducing the severity and duration of symptoms, and they can prevent transmission if given early. But antibiotic resistance is a growing concern. In some regions, particularly in Asia, strains of Bordetella pertussis resistant to macrolides have been reported. While resistance in Norway is still low, the threat is real.

If azithromycin fails, clinicians must turn to alternatives like trimethoprim-sulfamethoxazole, which has more side effects and is less well-tolerated in infants. The options are limited, and resistance could make treatment significantly harder. This is why prevention through vaccination remains the cornerstone of pertussis control. Antibiotics are a backup, not a solution.

The emergence of resistance is linked to overuse of macrolides, not just for pertussis but for other respiratory infections. Reducing unnecessary antibiotic prescriptions is a public health priority, but it is a slow process. In the meantime, clinicians must be vigilant, testing for resistance when treatment fails.

This adds another layer of complexity to an already challenging disease. The resurgence of pertussis is not just a failure of vaccination timing; it is also a reminder that our tools are not infallible. We need to use them wisely, and that means preventing infections in the first place.

Lessons from Other High-Income Countries

Norway is not alone in facing this resurgence. The UK and Australia have experienced similar waves of pertussis, and their responses offer lessons. The UK introduced maternal pertussis vaccination in 2012, offering the vaccine to pregnant women between 16 and 32 weeks of gestation. This has been highly effective, reducing the incidence of pertussis in infants under three months by over 90%. Australia followed a similar path, and both countries have seen a decline in infant hospitalizations.

Maternal vaccination works by boosting the mother's antibodies, which are then transferred to the baby. It is a safe and effective way to protect the most vulnerable infants. Norway has not yet adopted this strategy universally, though it is under discussion. The Norwegian Institute of Public Health has recommended it, but implementation has been slow.

Another lesson is the importance of booster doses. In the UK and Australia, booster doses are given to adolescents and adults, particularly those in close contact with infants. This reduces the pool of infection in the community and protects babies who are too young to be vaccinated. Norway has a booster at age 7, but not for adults. Expanding the booster program could help close the gap.

Finally, other countries have invested in robust surveillance and reminder systems. The UK uses a national immunization registry that tracks doses and sends reminders when children are due. Australia has a similar system. Norway has a registry, but it is not used as actively for outreach. Adopting these practices could make a significant difference.

Practical Steps to Close the Gap

So what can be done? The most immediate step is to reinforce on-time vaccination messaging. Parents need to understand that the first dose at six weeks is not a suggestion; it is a critical milestone. Public health campaigns should emphasize the severity of pertussis in infants and the fragility of the window.

Healthcare providers can also offer vaccination at every contact. If a child comes in for a check-up or a minor illness, that is an opportunity to check the immunization record and administer any due doses. This opportunistic approach has been shown to increase coverage. It requires that clinics have the vaccines on hand and that staff are trained to ask.

Digital reminders are another tool. Text messages or app notifications can reduce no-shows and remind parents of upcoming appointments. Some Norwegian municipalities have piloted such systems with good results. Scaling them up would be a low-cost, high-impact intervention.

Finally, monitoring coverage data in real time is essential. Public health authorities should track not just overall coverage but also the timeliness of the first dose. If a clinic or region is falling behind, targeted interventions can be deployed. This is not about blaming parents; it is about fixing the system.

There is no single solution. The resurgence of pertussis in Norway is a multifaceted problem, and it requires a multifaceted response. But the cost of inaction is clear: more sick infants, more hospitalizations, and more families devastated by a preventable disease. The window is closing, but it is not yet shut.

The Role of Community Immunity

Beyond individual vaccination, community immunity—often called herd immunity—plays a crucial role in protecting the most vulnerable. When a high percentage of the population is vaccinated, the spread of Bordetella pertussis is limited, reducing the chance that an unvaccinated or partially vaccinated infant will be exposed. In Norway, overall coverage for the full DTaP series is high, but pockets of under-vaccination can create local outbreaks.

One challenge is that the acellular vaccine, while safe, may not prevent colonization as effectively as the older whole-cell vaccine. This means that vaccinated individuals can still carry the bacteria and transmit it to others, even if they do not become ill themselves. This is a subtle but important point: the vaccine protects the individual from severe disease, but it does not always stop transmission. As a result, maintaining high coverage across all age groups is essential to reduce the overall burden of disease in the community.

Adolescents and adults can serve as reservoirs of infection, often with mild or atypical symptoms that go unrecognized. They may cough for weeks, unknowingly spreading the bacteria to infants who are not yet fully protected. This is why booster doses for older age groups are so important. By reducing the pool of infection, we can indirectly protect the youngest and most vulnerable.

In Norway, the booster at age 7 helps, but there is no routine booster for adults, except for healthcare workers in some settings. This leaves a gap in immunity that can be filled by the bacteria. Expanding booster recommendations to include adults who have contact with infants—such as new parents, grandparents, and childcare providers—could be a targeted and effective strategy. Some countries have implemented this as part of a cocooning approach, and it has shown promise.

Community immunity is not just about numbers; it is about equity. If vaccination rates are high in some neighborhoods but low in others, the benefits are unevenly distributed. Infants in under-vaccinated communities face a higher risk of exposure. Addressing these disparities requires outreach and engagement with the communities most affected. It is not enough to simply make vaccines available; we must also make them accessible and trusted.

The concept of community immunity also highlights the interconnectedness of health. When we protect ourselves, we protect others. This is especially true for pertussis, where the most severe outcomes occur in those who are too young to be vaccinated. By strengthening community immunity, we can close the window of vulnerability for all infants.

Economic and Social Costs

The resurgence of pertussis carries significant economic and social costs, both for families and for the healthcare system. For families, a sick infant often means missed work, sleepless nights, and the emotional toll of watching a child struggle to breathe. Hospitalizations can be lengthy, and some infants require intensive care. Even in mild cases, the persistent cough can last for weeks or months, disrupting family life and causing considerable stress.

For the healthcare system, each hospitalization for pertussis represents a substantial cost. While exact figures are difficult to pin down, estimates in other high-income countries suggest that the cost of a single infant hospitalization for pertussis can run into the tens of thousands of dollars, including intensive care, medications, and follow-up visits. When multiplied by the number of cases, the financial burden becomes clear. These are resources that could be used for other pressing health needs.

There is also a broader societal cost. Pertussis outbreaks can strain public health resources, diverting attention and funding away from other priorities. Outbreak investigations, contact tracing, and public communication campaigns all require time and money. In a country like Norway, with a robust healthcare system, these costs are manageable, but they are not trivial.

Prevention is not only medically effective but also economically sensible. Vaccination is one of the most cost-effective public health interventions available. The cost of a vaccine dose is minuscule compared to the cost of treating a severe case. Investing in on-time vaccination and catch-up programs is likely to yield significant returns in terms of reduced healthcare expenditures and improved quality of life.

Beyond the direct costs, there is the intangible cost of fear and anxiety. Parents who have heard about the resurgence may worry about every cough their baby makes. This fear can lead to unnecessary emergency room visits and increased stress. Public health messaging that is clear and reassuring can help mitigate this, but it requires ongoing effort.

Ultimately, the economic and social costs of pertussis are a reminder that vaccine-preventable diseases are not just a medical issue; they are a societal issue. The decisions we make about vaccination affect not only our own health but also the health of our communities and the sustainability of our healthcare systems. By addressing the root causes of delayed vaccination, we can reduce these costs and protect the most vulnerable members of society.

Navigating the Path Forward

As Norway grapples with this resurgence, it is clear that no single intervention will be sufficient. A comprehensive strategy is needed, one that combines education, access, and system-level changes. The lessons from other countries provide a roadmap, but they must be adapted to the Norwegian context.

One key element is improving the timeliness of the first dose. This may require more flexible clinic hours, walk-in vaccination services, or even home visits for families who face significant barriers. It also requires clear communication about why the six-week mark is so important. Parents should not have to navigate the system alone; they should be supported at every step.

Another element is strengthening surveillance and response. Real-time data on vaccination coverage and disease incidence can help identify problem areas early and guide targeted interventions. If a particular clinic or region is falling behind, resources can be deployed to address the issue. This is not about punishment but about problem-solving.

Finally, there is a need for ongoing research. The acellular vaccine has been a workhorse for decades, but its limitations are becoming clearer. New vaccines, such as those containing additional antigens or adjuvants, are being developed. These could provide longer-lasting immunity and better protection against transmission. Investing in this research is essential for the long-term control of pertussis.

The path forward is not simple, but it is clear. By focusing on the window of vulnerability, we can protect the infants who are most at risk. By strengthening community immunity, we can reduce the spread of the bacteria. And by addressing the social and economic barriers to vaccination, we can ensure that all families have the opportunity to protect their children.

Whooping cough is a disease that we know how to prevent. The tools are available, and the science is sound. What is needed is the will to use them effectively. Norway has the resources and the expertise to turn the tide. The question is whether we have the collective commitment to do so.

This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider for guidance on vaccination and health decisions.